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Objective: The aim of this study is to assess the response of patients with nondysgerminomatous ovarian
germ-cell tumors (NDOGCT) to platinum-based chemotherapy and to determine association of prog-
nostic factors to relapse of disease.
Methods: We retrospectively reviewed 21 patients who had surgical resection of nondysgerminomatous
ovarian germ-cell tumors (NDOGCT) and received adjuvant chemotherapy in Vali-e-Asr Hospital, Tehran,
Iran during 1997–2004. The median age at presentation was 18 years and the median follow-up was
20 months. Histological type of tumors included the following: immature teratoma (n ¼ 7), mixed germ-
cell tumor (n ¼ 7), yolk sac tumors (n ¼ 4), and embryonal carcinoma (n ¼ 3). Distribution by stage at the
time of surgery was as follows; stage I (n ¼ 10), stage III (n ¼ 6), and stage IV (n ¼ 5).
Results: Sixteen patients underwent unilateral salpingo-oophorectomy and 5 patients underwent cys-
tectomy. After the initial surgery, 13 patients immediately received chemotherapy and the other 8
patients received chemotherapy at a median time of 5.5 months (range, 1–40 months). Postoperative
chemotherapy included the following: bleomycin, etoposide, and cisplatin (n ¼ 17); vincristine, actino-
mycin-D, and cyclophosphamide (n ¼ 2); methotrexate, etoposide, and cisplatin (n ¼ l); and cisplatin
(n ¼ l). Thirty-one percent of the patients suffered a relapse after platinum-based combination chemo-
therapy. The median disease-free survival was 40 months and the median overall survival was
50 months. The 5-year survival rate was 39%.
Conclusions: This study showed that stage at the initial surgery, residual disease and the interval from
initial diagnosis to the start of chemotherapy were possible prognostic factors for relapse. Also, our study
indicates that there may be a role for aggressive cytoreductive surgery in advance NDOGCT, and a need
for second-line combination chemotherapy.
 2008 Surgical Associates Ltd. Published by Elsevier Ltd. All rights reserved.1. Introduction
Ovarian germ-cell tumors (OGCT) are rare malignancies, repre-
senting approximately 5% of ovarian neoplasm. These tumors can
be grouped as dysgerminomatous and nondysgerminomatous. The
latter group is comprised predominantly of immature teratoma
tumors (ITT), or yolk sac tumors (YST), and mixed germ-cell tumors
(MGCT); it and also includes the uncommon histology of embryonal
carcinoma and choriocarcinoma.1 Germ-cell tumors may secrete
both or neither alpha-fetoprotein (AFP) and beta human chorionic
gonadotropin (b-hCG), depending on the kind of tumor.
Most nondysgerminomatous ovarian germ-cell tumors
(NDOGCT) are unilateral and predominantly occur in children,þ98 21 693 7321.
emmaghami).
ciates Ltd. Published by Elsevier Ltadolescents, and young women.2 They are frequently diagnosed by
the ﬁnding of a palpable abdominal mass that is often associated
with pain. Except for benign cystic teratoma, OGCTs are usually
rapidly enlarging abdominal masses that often cause considerable
abdominal pain. At times, the pain is exacerbated by rupture or
torsion of the neoplasm. One of the classic initial signs of OGCT is
hemoperitoneum caused by rupture of the capsule of the lesion as
it rapidly enlarges.3 Unilateral salpingo-oophorectomy with pres-
ervation of the contralateral ovary and the uterus in addition of full
staging is now considered to be the appropriate surgical treatment
for patients with NDOGCT.4 The standard approach for most
patients with OGCTs regardless of tumor stage is conservative
surgery and adjuvant chemotherapy. Amajority of these tumors are
conﬁned to one ovary (stage I).3
Before the initiation of effective chemotherapy, the treatment of
patients with endodermal sinus tumor (EST) of the ovary was
frustrating and the survival rate for patients with metastaticd. All rights reserved.
Table 1




Abdominal pain only 12 57.2
Abdominal distention 4 19
Abdominal pain and distention 2 9.5
Abnormal uterine bleeding 2 9.5
Respiratory signs 1 4.8
Histology:
Immature teratoma 7 33.3
Mixed germ-cell tumors 7 33.3
ECT þ YST 1
ITT þ YST 1
Dysgerminoma þ YST 1
Choriocarcinoma þ YST 1
Choriocarcinoma þ dysgerminoma 1
ECT þ choriocarcinoma þ dysgerminoma 2
YST total 4 19







ECT, embryonal carcinoma tumor; YST, yolk sac tumor; ITT, immature teratoma
tumor; AFP, alpha-fetoprotein.
a The percentage is that of patients in whom AFP was known.
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survived, despite most having stage I disease.5
Because NDOGCTs are rare, few prospective trials (no random-
ized trials) have been conducted that have speciﬁcally examined the
optimal approach to management in patients with these tumors.
Thus, the management principles adopted in these patients
frequently have been followed for testicular germ-cell tumors,
which share similar pathologic features and responsiveness to
chemotherapy. In the early 1970s, the combination of vincristine,
actinomycin-D, and cyclophosphamide (VAC) emerged as a stan-
dard chemotherpy.6 Williams et al., however, reported that the
bleomycin, etoposide, and cisplatin (BEP) combination was equally
as effective as the VBP combination, and less toxic in patients with
disseminated germ-cell tumors.7 Since the Williams study, several
other authors have reported encouraging results with the BEP
regimen. However, role of adjuvant chemotherapy in patients with
stage I of NDOGCT is questionable. Platinum-based chemotherapy is
the standard postoperative treatment for all patientswith advanced
NDOGCT malignancies. For patients with ITT plus peritoneal
spreading, chemotherapy is not required for grade 0 or 1 implants;
chemotherapy had uncertain importance for grade 2 lesions, but it
is warranted for grade 3 lesions. In a study in which most patients
underwent conservative surgery and adjuvant platinum-based
chemotherapy, the 5-year survival rates ranged from 82% to 100%
for patients with stage I nongerminomatous testicular germ-cell
tumors.8 Other studies showed the risk of relapse is less than 20% if
vascular invasion is absent.9 Tewari et al. showed the 5-year survival
rate was 93% but 20 of the 72 cases in his study were dysgermi-
nomas.10 In our study, we retrospectively reviewed a series of
patients with NDOGCT to determine clinical characteristics, the
efﬁcacy of various treatment regimens, and prognostic factors.
2. Materials and methods
We conducted a retrospective study of patients at Vali-e-Asr
Hospital in Tehran with NDOGCT during the period 1997–2004.
Initial surgery in some patients was performed by a surgeon from
the Gynecology Oncology group. Twenty-one patients with
NDOGCT satisﬁed the criteria of histological diagnosis of non-
germinatous ovarian germ-cell tumor for inclusion in the study.
Their tumor histologies had been determined at presentation and
they had also been followed up for 3–72 months.
The patients had been staged prospectively on the basis of
surgical ﬁndings and imaging results. The staging results were
reviewed retrospectively by one of the investigators, and patients
were re-staged according to the most recent International Federa-
tion of Gynecology and Obstetrics (FIGO) staging criteria.
All patients received adjuvant chemotherapy. The chemo-
therapy regimens used were as follows: BEP (bleomycin 20 mg/m2
on day one of each cycle, cisplatin 20 mg/m2 and etoposide 100 mg/
m2 on days 1–5 every 3 weeks) and VAC (vincristine 1.5 mg/m2 on
day 1 of each cycle, actinomycin-D 300 mg/m2 daily, cyclophos-
phamide 150 mg/m2 daily, every 4 weeks).
Patients were followed up every month for the ﬁrst and second
years after the end of chemotherapy, every 2 months during the
third and fourth years, and every 4 months thereafter. Complete
remissionwas deﬁned as the normalization of AFP and b-hCG levels
and resolution of all residual masses. Also, efﬁcacy of platinum-
based chemotherapy was assessed with normalizationof tumor
markers and decrease in tumoral lesion in pelvic examination or
imaging studies. Survival was considered from the date of initial
surgery.
Data are presented as counts, medians or percentages. Fisher’s
exact test was used for univariate analysis. P values less than 0.05
were considered statistically signiﬁcant. Multivariate analysis was
not carried out because of the small number of events. Overallsurvival and disease-free survival were computed using the
Kaplan–Meier method.3. Results
A total of 21 patients who had been seen during 1997–2004
were included in the study. The median age at presentation was
18 years (range, 12–32 years). The most common presenting
symptom was abdominal pain (Table 1). Only one patient was
premenarchal. Histological evaluation revealed 7 patients had
immature teratoma (ITT), 7 mixed germ-cell tumor (MGCT), 4 yolk
sac tumors (YST), and 3 embryonal carcinoma (ECT) (Table 1). In the
patients with ITTs, 4 patients had grade II disease and 3 had grade
III disease. Four of seven patients with MGCT had elements of YST
(Table 1). Distribution by stage at the time of surgery was as
follows: stage I (n ¼ 10), stage III (n ¼ 6), and stage IV (n ¼ 5). One
patient with stage I MGCT had extra ovarian disease (stage IC) and
two patients had bilateral ovarian disease (one with stage I had
MGCT and one with stage III had YST).
The median age of patients with ESTs and ITTs was 16 years
(range,16–22 years) and 17 years (range,14–20 years), respectively.
The median age of patients with MGCT and YST was 21 years
(range, 12–31 years) and 25 years (range, 20–32 years),
respectively.
Initial surgery included unilateral salpingo-oopherectomy
(USO) in 16 (76.2%) patients and cystectomy in 5 (23.8%) patients. In
14 cases, surgery was performed by a general gynecologist, and in
7 cases it was performed by a gynecology oncologist. Although 11
patients out of 14 that underwent surgery by a general gynecologist
had recurrence or persistent disease, they had no residual disease
at the time of commencing chemotherapy. Other patients under-
went two procedures.
In four patients, we performed total abdominal hysterectomy
and bilateral salpingo-oopherectomy. These patients had stage III to
IV; three of these patients died. Other patients underwent USO or
cystectomy.
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a normal level of AFP. Eleven patients had pelvic and abdominal
metastases. Four of these 11 patients also had metastases in the
lung, and three patients also had liver metastases. Two of the
eleven patients with metastases had lymph node involvement.
AFP levels were known for 17 patients, and they were raised in
14 (82.4%) of them (Table 1). The AFP levels according to tumor type
are shown in Table 2. Seven patients with YST and ECT had elevated
AFP levels. Two of the four patients with YST had AFP levels
above10,000 ng/ml. The four patients with MGCT who had
elements of YST had elevated AFP levels; three had AFP levels above
1000 ng/ml. b-hCG level for our entire patient cohort was not
available.
At the time of commencing postoperative chemotherapy, 15
patients (71.4%) had no residual disease, but 10 of these patients
had increasingAFP levels. After initial surgery, 13 patients imme-
diately received chemotherapy and the other 8 patients received
chemotherapy at a median of 5.5 months (range, 1–40 months).
Postoperative systemic chemotherapy was administered to all
patients and consisted of the following: VAC (n ¼ 2); BEP (n ¼ 17);
methotrexate, etoposide, and cisplatin (n ¼ 1); and cisplatin
(n ¼ 1). Seven patients had no tumor markers and 12 patients had
tumor markers that became negative at a median of 3 months
(range, 1–10 months) after chemotherapy. Only two patients had
interval debulking and both of these patients had IT (one at stage
IIIC and one at stage IV). Thirteen (62%) patients achieved
a complete response at a median of four cycles of chemotherapy.
Eight (38%) of the 21 patients relapsed during the study period;
their characteristics are shown in Table 3. Three patients had ITT;
one patient had grade 3, stage I disease; one patient had grade 2,
stage IV disease; and another had stage III disease with unknown
grade. All three patients with YST relapsed. Only one patient with
EST relapsed. Cytoreductive surgery was performed in ﬁve patients
with relapses.
Among the patients with MGCT, one developed a recurrence.
Her stage of disease was stage I with a histology composed of
elements of choriocarcinoma and dysgerminoma. Univariate anal-
ysis showed that residual disease and the time from initial diag-
nosis to the start of chemotherapy were possible prognostic factors
for relapse. In patients with residual disease, the rate of recurrence
was 83.3% versus 20% in patients without residual disease
(P ¼ 0.014). Only 7.7% of the patients who immediately began
chemotherapy developed a recurrence, while 87.5% of patients who
received chemotherapy with delay developed a recurrence
(P ¼ 0.001). Six (31.6%) of the 19 patients who received platinum-
based chemotherapy had a relapse, and both patients who received
the VAC regimen relapsed. Although this difference was not
statistically signiﬁcant (P ¼ 0.133), ﬁve patients died of NDOGCT
(Table 3).
Three of the six patients who relapsed after BEP chemotherapy
then received VAC as second-line chemotherapy. However,after
a brief remission (5–13 months) their disease progressed and all
patients died (Table 3).Table 2
Alpha-fetoprotein levels analyzed according to histologic classiﬁcation
AFP levels (ng/ml) ITT MGCT YST EC
7 7 4 3
Unknown 3 1 – –
Normal 2 1 – –
11–1000 2 2 1 2
1001–10,000 – 3 1 1
> 10,000 – – 2 –
ITT, immature teratoma; MGCT, mixed germ-cell tumor; YST, yolk sac tumor; ECT,
embryonal carcinoma tumor; AFP, alpha-fetoprotein.The median follow-up was 20 months (range: 3–72 months).
Overall, 16 patients (76.2%) were alive without evidence of disease
at a median follow-up of 20.5 months (range, 3–46 months). The
median disease-free survival was 40 months (95% conﬁdence
interval, 26.8–53.2), as shown in Fig. 1. The median overall survival
was 50 months (95% conﬁdence interval, 4.8–95.2). The 5-year
actuarial survival rate was 39% (Fig. 2).
Two patients who conceived had a total of two pregnancies. Two
infants were born who were completely normal.
4. Discussion
In our study, the median age of patients was 18 years (range,12–
72 years). The most common symptoms were abdominal pain and
distention (85%). The most common histological types were
immature teratoma and mixed germ-cell tumors (1/3 patients
each). More than 50% of patients (11 patients) were in advanced
stage. Alpha-fetoprotein was the only measurable tumor marker
that was increased in 2/3 patients and was associated signiﬁcantly
with relapse and poor prognosis.
In this study 6 (31%) of the 19 patients who received platinum-
based chemotherapy had relapses. Residual disease and the dura-
tion between initial diagnosis and the start of chemotherapy were
prognostic factors for relapse. These delays in the beginning of
chemotherapy were always due to socioeconomic causes. The
outcome of patients after relapse was poor. However after begin-
ning the chemotherapy regimen, it was carried through in all cases.
In other studies, almost 70% of ovarian tumors are of germ-cell
origin in the ﬁrst two decades of life.11,12 In contrast to the relatively
slow-growing epithelial ovarian tumors, germ-cell malignancies
grow rapidly and often are characterized by subacute pelvic pain
related to capsular distention, hemorrhage, or necrosis.13
Some studies showed also that YST histology and high AFP levels
were associated with a poor outcome.1,14 Other studies have
reported that up to 39% of patients relapsed after the end of
chemotherapy regimens,15,17 including BEP, which is the current
standard therapy.16,18 In the Mitchell et al. study, relapses occurred
in 14% of the patients who received platinum-based chemo-
therapy.1 In our study an AFP level higher than 1000 ng/ml was
useful to predict relapse.
Most authors report that more than 90% of patients with
minimal tumor burden were cured.8,9,15,16 Patients with bulky
nondysgerminomatous tumors do not enjoy sustained remission
rates.19
In a study conducted in India by Bafna et al., 40% of the patients
who underwent surgery outside an oncology setting experienced
considerable delay after their initial surgery and presented with
bulky disease before chemotherapy.19
Also, some GOG studies suggest that patients with advanced
disease who undergo surgical resection plus adjuvant chemo-
therapy have a higher complete remission rate than patients who
are not debulked.20 Because of the rapid growth of tumors in some
patients, treatment should be initialized as soon as possible after
surgery, preferably within 7–10 days.19 In developing countries, for
socioeconomic reasons there is often a considerable delay between
the time of initial surgery and the start of chemotherapy. However,
this delay occurs in most patients who undergo operations outside
of an oncology setting. This is a problem because even a short delay
can result in rapid growth of a tumor, especially if the tumor is
nondysgerminomatous. In most of the patients in this study,
surgery was performed by a general gynecologist, and chemo-
therapy started without delay in only 13 patients. The centraliza-
tion of primary ovarian cancer surgery to oncology settings should
improve patients’ survival in developing countries.
The outlook for patients with early-stage NDOGCT is usually
very good. In a GOG trial of 93 patients with stage I NDOGCT, three
Table 3
Characteristics of 8 patients with relapse
Age
(years)














13a MCGT I N Neg. Pos. BEP (4) Sparing 19 Non 41 (L)
14 IT (UK) III UK Pos. Pos. VAC (6) TAH þ BSO 40 BEP (4) 50 (D)
16 IT (G2) IV 175 Pos. Pos. BEP (6) Sparing 4 VAC (3) 17 (D)
17 IT (G3) I UK Neg. Neg. BEP (4) Sparing 24 Non 35 (L)
22 EC IV 210 Pos. Neg. BEP (1) Sparing 11 VAC (6) 16 (D)
23 YST III 2000 Pos. Pos. VAC (1) TAH þ BSO 2 BEP (5) 8 (L)
27 YST I 11000 Neg. Pos. BEP (6) Sparing 40 Non 72 (D)
32a,b YST III 1480 Pos. Neg. BEP (6) TAH þ BSO 6 VAC (6) 18 (D)
AFP, alpha-fetoprotein; MGCT, mixed germ-cell tumor; IT, Immature teratoma; UK, unknown; YST, yolk sac tumor; EC, embryonal carcinoma; N, normal; L, living; D, dead.
a Bilateral malignant ovarian tumors.
b Pregnant woman.
























Fig. 1. Disease-free survival.
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study excluded patients with stage I grade I ITT. Eighty-nine (96%)
patients were disease free at follow-up and another two patients
were disease free after resection of ITT at second-look surgery,
while two patients in the GOG trial were found to have developed
hematological malignancies after chemotherapy.21
In our study eight patients relapsed after surgical staging and
adjuvant chemotherapy. Treatment was successful in only three
cases and all the others died due to relapse. On the other hand 4 out
of 6 (67%) patients treated with platinum-based chemotherapy
died. It is evident that they were mostly at an advanced stage (3 out
of 4 were stage III or IV). So managing NDOGCT may require
a different strategy, especially in advanced stages and after relapse.
In our study, survival was not improved for patients who
underwent extensive surgery rather than fertility-sparing surgery
(Table 3). There is no clear evidence that anything more than
unilateral ovarian surgery is required if effective platinum-based
chemotherapy is administered, so routine surgery should be
limited to unilateral oopherectomy, and the disease should by
carefully staged.18,19 It is still unclear whether cystectomy alonewill
also be safe. In the Beiner et al. study, the eight patients who
underwent cystectomy were diagnosed with immature teratoma
(three grade I, four grade II, and one grade III) on ﬁnal pathology
following surgery. All except three patients (two with grade I and
onewith grade II disease) received adjuvant chemotherapy. Follow-
up was available for all patients, with a median duration of 4–
7 years. No recurrences were obscured during this period.4 Further
studies will need to address the issue that cystectomy alone will
also be safe. Fertility-sparing surgery should be considered in
patients with early-stage disease, and care should be taken when
performing the surgery in patients with recurrent disease and
advanced stage disease.13,18
In 1976, Norris and colleagues reported that patients with
early stage ITT (grades 2 and 3) had a high relapse rate after
surgery alone when followed up by observation only; 48% of such
patients died of recurrence.22 These data showed that observation
is appropriate only in patients with grade 1, stage IA ITT. However,
these data were obtained when computed tomography was not
available, so staging may have been inadequate. Bonazzi and
colleagues followed a policy of observation in 22 women with ITT
with either stage I or II, grade 1 or 2 tumors; no malignant
relapses occurred with a median follow-up of 4 years. However,
three patients later underwent surgery to remove mature
teratomas.23
Another study examined 15 patients with stage IA NDOGCT
who were managed by surveillance and surgery. Of the nine cases
of ITT (grade 2 or 3), one patient showed relapse at 15 months
while pregnant and died due to thromboembolism. Six other
patients with stage IA mixed tumors or EST were managed on
a surveillance policy, with two patients relapsing 4 months aftersurgery. Both of these patients were alive and were disease-free
after combination chemotherapy. Thus, the authors of this study
consider that some patients with early-stage NDOGCT have a low
risk of relapse and may not require adjuvant chemotherapy, but
chemotherapy is effective at relapse.24 It is possible that intensive
surveillance of patients and treatment with chemotherapy at
relapse only may not compromise patient outcome. Furthermore,
such an approach would reduce the risk of secondary hemato-
logical malignancy after cisplatin or particularly etoposide
chemotherapy.25,26
The growing teratoma syndrome (GTS) is an extremely rare
metastatic complication of a malignant germ-cell tumor. The
histology of the metastasis is of mature teratoma with no
malignant element,27 but we did not encounter any case of
growing teratoma syndrome. Fertility-preserving treatment for
malignant germ-cell tumors of the ovary, even in advanced stages,
allowed these young women to conceive and have children. In the
Tangir et al. study, a total of 106 patients with malignant germ-
cell tumors of the ovary were included and a total of 38 children
were born to these women.28 In our study, two patients who
conceived gave birth to two normal infants, but the follow-up
time was short.
























Fig 2. Overall survival.
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Our study showed that residual disease after initial surgery, the
time from initial diagnosis to the start of chemotherapy, and stage
at the initial surgery were possible prognostic factors for relapse.
Also, our study showed that the treatment and management of
NDOGCT is a problem and that further studies of combination
chemotherapy regimens, especially for advanced and recurrent
diseases, are needed.Conﬂict of interest
None declared.
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